TR200003803T2 - Üreme hatalı yeniden bağlayıcı mutasyonlu ana son arttırıcı - Google Patents

Üreme hatalı yeniden bağlayıcı mutasyonlu ana son arttırıcı

Info

Publication number
TR200003803T2
TR200003803T2 TR2000/03803T TR200003803T TR200003803T2 TR 200003803 T2 TR200003803 T2 TR 200003803T2 TR 2000/03803 T TR2000/03803 T TR 2000/03803T TR 200003803 T TR200003803 T TR 200003803T TR 200003803 T2 TR200003803 T2 TR 200003803T2
Authority
TR
Turkey
Prior art keywords
reproductive
defective recombinant
major end
mutation
recombinant mutation
Prior art date
Application number
TR2000/03803T
Other languages
English (en)
Inventor
E. Brough Douglas
Kovesdi Imre
Original Assignee
Genvec Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc. filed Critical Genvec Inc.
Publication of TR200003803T2 publication Critical patent/TR200003803T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Mevcut bulus, EI bölgesinde bir bozukluk ve MLP bölgesinde bir mutasyonu olan bir genoma sahip olan bir yeniden baglayici adenovirüs sunar. Bulus ayrica, bulusa konu olan virüs de dahil olmak üzere bu tür virüslerin stoklarini da sunar. Bulus ayrica, yeniden baglayici adenovirüsün hücre soylarinin üretilmesini de sunar.
TR2000/03803T 1998-06-26 1999-06-24 Üreme hatalı yeniden bağlayıcı mutasyonlu ana son arttırıcı TR200003803T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/105,515 US6113913A (en) 1998-06-26 1998-06-26 Recombinant adenovirus

Publications (1)

Publication Number Publication Date
TR200003803T2 true TR200003803T2 (tr) 2001-04-20

Family

ID=22306280

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03803T TR200003803T2 (tr) 1998-06-26 1999-06-24 Üreme hatalı yeniden bağlayıcı mutasyonlu ana son arttırıcı

Country Status (12)

Country Link
US (2) US6113913A (tr)
EP (1) EP1088092A1 (tr)
JP (1) JP2002519036A (tr)
AU (1) AU4716399A (tr)
BR (1) BR9911539A (tr)
CA (1) CA2332181A1 (tr)
HU (1) HUP0301318A2 (tr)
IL (1) IL140274A0 (tr)
MX (1) MXPA00012617A (tr)
PL (1) PL345517A1 (tr)
TR (1) TR200003803T2 (tr)
WO (1) WO2000000628A1 (tr)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2344100A (en) * 1998-11-18 2000-06-05 Canji, Inc. Viral vectors with late transgene expression
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US7653769B2 (en) * 2006-12-14 2010-01-26 International Business Machines Corporation Management of devices connected to infiniband ports
JP4550421B2 (ja) * 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
US20030158112A1 (en) * 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
EP1492890A4 (en) * 2002-03-29 2006-10-18 Merck & Co Inc METHODS OF LARGE SCALE PRODUCTION OF ADENOVIRUS AND ADENOVIRUS SEMEN COLLECTIONS
CA2503905A1 (en) * 2002-09-16 2004-03-25 Plexxikon, Inc. Crystal structure of pim-1 kinase
CA2507036A1 (en) * 2002-12-02 2004-06-17 Genvec, Inc. Materials and methods for treating ocular-related disorders
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US20050170431A1 (en) * 2003-02-28 2005-08-04 Plexxikon, Inc. PYK2 crystal structure and uses
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US20050164300A1 (en) * 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
JP2007511507A (ja) 2003-11-14 2007-05-10 ジェンベク、インコーポレイティッド 癌を処置するための治療レジメン
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
US20070066641A1 (en) * 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
DE602005015332D1 (de) * 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
WO2005089811A1 (en) * 2004-03-12 2005-09-29 Genvec, Inc. Materials for treating vascular leakage in the eye
US20070207166A1 (en) 2004-04-12 2007-09-06 Genvec, Inc. Method of Using Adenoviral Vectors to Induce an Immune Response
JP2008503446A (ja) * 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
CA2583428A1 (en) * 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
US20060188481A1 (en) * 2005-02-22 2006-08-24 Saitama Medical School Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
WO2006108707A1 (en) * 2005-04-11 2006-10-19 Crucell Holland B.V. Virus purification using ultrafiltration
CA2608733A1 (en) * 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
PL1893612T3 (pl) * 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
AU2006284756B2 (en) 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2007059461A2 (en) 2005-11-10 2007-05-24 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
AU2007336811A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US20090202492A1 (en) * 2008-01-25 2009-08-13 University Of South Florida Adenovirus vaccine utilizing ikk as adjuvant
BRPI0921651A2 (pt) * 2008-11-03 2015-08-18 Crucell Holland Bv Método para produzir adenovírus recombinante, e partículas virais, e, biorreator
EP2387627B1 (en) 2009-01-15 2016-03-30 Adaptive Biotechnologies Corporation Adaptive immunity profiling and methods for generation of monoclonal antibodies
WO2010114928A2 (en) * 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
BR112012008507B8 (pt) 2009-10-15 2021-05-25 Crucell Holland Bv método para purificar partículas de adenovírus a partir de uma suspensão de célula
JP5393896B2 (ja) 2009-10-15 2014-01-22 クルセル ホランド ベー ヴェー アデノウイルス粒子の精製方法
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
EP2853266B1 (en) 2009-11-09 2018-01-31 Genvec, Inc. Method of propagating monkey adenoviral vectors
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
ES2578514T3 (es) 2010-02-15 2016-07-27 Crucell Holland B.V. Método para la producción de vectores adenovíricos
CN103038343A (zh) 2010-03-23 2013-04-10 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
SG10201600912SA (en) 2011-03-04 2016-03-30 Intrexon Corp Vectors conditionally expressing protein
JP6113151B2 (ja) 2011-05-17 2017-04-12 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節およびその適応症
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
US9233153B2 (en) 2011-10-05 2016-01-12 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
US9617560B2 (en) 2011-10-05 2017-04-11 Genvec, Inc. Simian (gorilla) adenovirus or adenoviral vectors and methods of use
US9580476B2 (en) 2011-10-05 2017-02-28 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (RSV) vaccine
US9629906B2 (en) 2011-10-05 2017-04-25 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
WO2013116591A1 (en) 2012-02-02 2013-08-08 Genvec, Inc. Adenoviral vector-based malaria vaccine
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
MY169352A (en) 2012-03-22 2019-03-25 Janssen Vaccines & Prevention Bv Vaccine against rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
WO2013180967A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Herpes simplex virus vaccine
WO2013181128A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Modified serotype 28 adenoviral vectors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20220139415A (ko) 2013-03-13 2022-10-14 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 선융합(prefusion) RSV F 단백질 및 이의 용도
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
BR112015031509B1 (pt) 2013-06-17 2023-05-09 Janssen Vaccines & Prevention B.V. Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende
MX369156B (es) 2013-09-19 2019-10-30 Janssen Vaccines & Prevention Bv Formulaciones de adenovirus mejoradas.
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
PT3215187T (pt) 2014-11-04 2018-11-27 Janssen Vaccines & Prevention Bv Vacinas terapêuticas contra hpv16
EP3271729B1 (en) 2015-03-18 2020-09-23 Janssen Vaccines & Prevention B.V. Assays for recombinant expression systems
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
CA2991540A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MX2018002106A (es) 2015-08-20 2018-06-15 Janssen Vaccines & Prevention Bv Vacunas terapeuticas contra el hpv18.
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MX2018012095A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Vacuna contra vrs.
WO2017174568A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins
JP7053491B2 (ja) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ
US11473105B2 (en) 2016-05-12 2022-10-18 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
MX2018015540A (es) 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
CA3038968A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
WO2018136202A2 (en) 2016-12-23 2018-07-26 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
US20200032223A1 (en) * 2017-04-10 2020-01-30 Epicentrx, Inc. Method for producing recombinant virus
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
CA3073790A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
EA202091104A1 (ru) 2017-10-31 2020-08-12 Янссен Вэксинс Энд Превеншн Б.В. Аденовирус и пути его применения
CN111295391B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
EP3704138A1 (en) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
AU2018359494A1 (en) 2017-10-31 2020-04-23 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
PT3743106T (pt) 2018-01-23 2022-08-24 Janssen Vaccines & Prevention Bv Vacinas contra o vírus da influenza e suas utilizações
SG11202008508QA (en) 2018-03-06 2020-10-29 Precigen Inc Hepatitis b vaccines and uses of the same
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
JP2022530439A (ja) 2019-04-25 2022-06-29 ヤンセン ファッシンズ アンド プリベンション ベーフェー 組換えインフルエンザ抗原
CA3140234A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
BR112021022087A2 (pt) 2019-05-15 2021-12-28 Janssen Vaccines & Prevention Bv Coadministração de vacina sazonal contra influenza e vacina contra vírus respiratório sincicial à base de adenovírus
US20230250135A1 (en) 2019-09-05 2023-08-10 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US20220372515A1 (en) 2019-10-03 2022-11-24 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
JP2022551483A (ja) 2019-10-08 2022-12-09 トラスティーズ オブ ボストン カレッジ 複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
EP4135757A1 (en) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2023091696A1 (en) 2021-11-19 2023-05-25 Christiana Care Gene Editing Institute, Inc. Adenovirus delivery system for cancer treatment
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
FR2704234B1 (fr) 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2707664B1 (fr) 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
EP0763103A4 (en) * 1994-04-28 1998-07-15 Univ Michigan GENE DELIVERY VECTOR USING PLASMID DNA ENCAPSULATED IN ADENOVIRUS AND CELL LINE OF ENCAPSIDATION
EP0784690B1 (en) * 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors

Also Published As

Publication number Publication date
WO2000000628A1 (en) 2000-01-06
BR9911539A (pt) 2001-03-20
HUP0301318A2 (hu) 2003-08-28
CA2332181A1 (en) 2000-01-06
WO2000000628B1 (en) 2000-03-16
MXPA00012617A (es) 2002-08-20
PL345517A1 (en) 2001-12-17
EP1088092A1 (en) 2001-04-04
JP2002519036A (ja) 2002-07-02
US6113913A (en) 2000-09-05
AU4716399A (en) 2000-01-17
IL140274A0 (en) 2002-02-10
US6458578B1 (en) 2002-10-01

Similar Documents

Publication Publication Date Title
TR200003803T2 (tr) Üreme hatalı yeniden bağlayıcı mutasyonlu ana son arttırıcı
BR9405507A (pt) Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
DE60120356D1 (de) Verbesserte galactosylierung von rekombinanten proteinen
DK1015622T3 (da) Praktisk sialylering in vitro af rekombinante glycoproteiner
TR199700358A2 (tr) Interferon birlesimler.
DK1533380T3 (da) Rekombinant proteinproduktion i en human celle indeholdende mindst ét E1-protein af adenovirus
TR199801302T2 (tr) Ikame edilmis aza ve diazasikolopentan ve siklooktan bilesikleri.
CY1105772T1 (el) Συνθεσεις και μεθοδοι για βελτιωμενη κυτταρικη καλλιεργεια
EP1282722A4 (en) STABILIZED PROTEINS
HUP0002985A2 (hu) Glicirrizinsavat és legalább egy antivirális hatású proteint tartalmazó vírusellenes gyógyszerkészítmény
NO971247L (no) Defektive, rekombinante adenoviruser med inaktivt IVa2-gen
ATE253094T1 (de) Polimerischen stabilisatoren mit hoher affinität zur pulpen
AU1217101A (en) Bridge interface circuit
YU31697A (sh) Varijante aprotinina sa poboljšanim svojstvima
NO990849D0 (no) Substituerte 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyklohepta (b) benzofuraner
WO2000026395A3 (en) Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors
DE69933131D1 (de) Zellen zur produktion von helper-abhängigen adenoviren-vektoren
DK0942992T3 (da) O-fucosyltransferase
DE69820220D1 (de) Vorspannungsschaltung hoher impedanz für wechselstromsignalverstärker
TR200000234T2 (tr) Samandan yapısal pano
DE69927845D1 (de) Verwendung des vaskularen endothelialen wachstumsfaktors (vegf)
IT1270513B (it) Bruciatore particolarmente adatto per segatura.
ATE290632T1 (de) Verbesserung für glasgedeckte dächer
DE59909869D1 (de) Beeinflussung von hyperaktiven t-zellen durch proteolytische enzyme
DE69937998D1 (de) Antiproliferative und antivirale proteine und peptide